Integral Diagnostics Ltd
IDX: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|$@B<>> | LOCK|$h | LOCK|>tWKGwp |
Integral Diagnostics Earnings: Labor Costs Weigh on Margins, but Poised to Expand
No-moat Integral Diagnostic’s interim fiscal 2025 underlying Australian revenue grew a respectable 8%, driven by 5% average fee growth on increases in government funding and continued favorable mix impact, but was below industry growth of 11%. Underlying group EBITDA also grew 8% to AUD 47 million, but the market was clearly disappointed about profitability.
